Back to Search
Start Over
Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- Source :
- Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, p546-546, 1p
- Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 41
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 161485007
- Full Text :
- https://doi.org/10.1200/JCO.2023.41.4_suppl.546